Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
422
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma

Tomiyuki Sugia Department of Pharmacy, Eiju General Hospital, Tokyo, Japan;b Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, JapanCorrespondence[email protected]
,
Yasuo Nishigamia Department of Pharmacy, Eiju General Hospital, Tokyo, Japan
,
Hirohisa Saigoa Department of Pharmacy, Eiju General Hospital, Tokyo, Japan
,
Homare Hanaia Department of Pharmacy, Eiju General Hospital, Tokyo, Japan
,
Keisuke Takabatakea Department of Pharmacy, Eiju General Hospital, Tokyo, Japan
,
Mitsuo Mitab Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan
,
Shin Oharac Department of Hematology, Eiju General Hospital, Tokyo, Japan
,
Shiro Idec Department of Hematology, Eiju General Hospital, Tokyo, Japan
,
Tomoyuki Uchidac Department of Hematology, Eiju General Hospital, Tokyo, Japan
,
Morihiro Inouec Department of Hematology, Eiju General Hospital, Tokyo, Japan
&
Masao Hagiharac Department of Hematology, Eiju General Hospital, Tokyo, Japan
 show all
Pages 1405-1410 | Received 11 Aug 2020, Accepted 06 Jan 2021, Published online: 28 Jan 2021

References

  • Nardone B, Wu S, Garden BC, et al. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13(4):424–429.
  • Tinsley SM, Kurtin SE, Ridgeway JA. Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S64–S69.
  • Barley K, He W, Agarwal S, et al. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leuk Lymphoma. 2016;57(11):2510–2515.
  • Iida S, Chou T, Okamoto S, et al. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol. 2010;92(1):118–126.
  • Ando K, Chou T, Suzuki K, et al. [Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study] . Rinsho Ketsueki. 2017;58(11):2219–2226.
  • Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–2132.
  • Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917.
  • Sviggum HP, Davis MD, Rajkumar SV, et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006;142(10):1298–1302.
  • Dote S, Ito K, Itakura S, et al. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study. Leuk Lymphoma. 2019;60(12):2975–2981.
  • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
  • Lee MJ, Wickner P, Fanning L, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167(1):127–131.
  • Yau P, Jimenez-Zepeda VH, Bailey K, et al. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center. Leuk Lymphoma. 2019;60(13):3199–3203.
  • Scott GB, Carter C, Parrish C, et al. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. Cell Immunol. 2015;297(1):1–9.
  • LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103(5):1787–1790.
  • Sekiguchi Y, Shimada A, Imai H, et al. Patient with refractory multiple myeloma developing eosinophilia after lenalidomide treatment and lung cancer 9 months later: case report and review of the literature. Indian J Hematol Blood Transfus. 2014;30(Suppl 1):264–270.
  • Shanbhag A, Pritchard ER, Chatterjee K, et al. Highly probable drug reaction with eosinophilia and systemic symptoms syndrome associated with lenalidomide. Hosp Pharm. 2017;52(6):408–411.
  • Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213–1223.
  • Costa F, Vescovini R, Bolzoni M, et al. Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget. 2017;8(32):53053–53067.
  • Vo MC, Anh-NguyenThi T, Lee HJ, et al. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. Exp Hematol. 2017;46:48–55.
  • Phan V, Ito T, Inaba M, et al. Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses. Blood Adv. 2020;4(15):3572–3585.
  • Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835–1844.
  • Berges C, Haberstock H, Fuchs D, et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology. 2008;124(2):234–246.
  • Heider U, Rademacher J, Kaiser M, et al. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma Leuk. 2010;10(2):134–137.
  • Mulder A, Heidt S, Vergunst M, et al. Proteasome inhibition profoundly affects activated human B cells. Transplantation. 2013;95(11):1331–1337.
  • NCCN clinical practice guidelines in oncology: Multiple Myeloma Version 4.2020. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.